<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5872">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085136</url>
  </required_header>
  <id_info>
    <org_study_id>1200.42</org_study_id>
    <secondary_id>2009-014563-39</secondary_id>
    <nct_id>NCT01085136</nct_id>
  </id_info>
  <brief_title>LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib</brief_title>
  <official_title>Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica</authority>
    <authority>Australia: Dept of Health and Ageing Therapeutic Goods Admin</authority>
    <authority>Austria: Medicines and Medical Devices Agency</authority>
    <authority>Belgium: Federal Agency for Medicinal and Health Products</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>China: Food and Drug Administration</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>India: Drugs Controller General of India</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Netherlands: Central Committee Research Involving Human Subjects</authority>
    <authority>Peru: Ministry of Health</authority>
    <authority>Poland: Registration Medicinal Product Medical Device Biocidal Product</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>South Korea: Ministry of Food and Drug Safety (MFDS)</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Taiwan: Department of Health</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this randomized, open-label, active-controlled, multi-center trial
      is to determine the efficacy of BIBW 2992 given as an add-on to chemotherapy in patients
      with NSCLC Stage IIIb or IV progressing after BIBW 2992 monotherapy compared to chemotherapy
      alone in this patient population. Patients on both treatment arms will receive best
      supportive care in addition to study treatment. Patients enrolled into the trial will be
      treated and followed until death or lost to follow-up. Additional information on the
      health-related quality of life (HRQOL) will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) Time as Determined by RECIST 1.1 for Part B.</measure>
    <time_frame>Every 8 weeks until the final follow-up visit in Part B, up to a total of 10 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS from the day of randomisation to the day of progression according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 for patients randomised to combination therapy with afatinib plus paclitaxel or to investigators choice of chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as Determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A</measure>
    <time_frame>tumour assessment was at screening (-28 days to screening) and every 6 weeks until the first follow-up visit in Part A, up to a total of 10 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A. PFS from the day of randomisation to the day of progression according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 for patients treated with Afatinib monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) as Determined by the Time From Randomization to Death in Part B</measure>
    <time_frame>from the date of randomisation to the date of death, up to a total of 10 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall survival was calculated as the time from the date of randomisation to the date of death. Patients for whom there was no evidence of death at the time of the analysis were to be censored on the date that they were last known to have been alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate According to RECIST 1.1 in Part B</measure>
    <time_frame>tumour assessment was every 8 weeks until the final follow-up visit in Part B, up to a total of 10 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective tumour response was defined as a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 and as assessed by the Investigator. For patients enrolled in Part B, a Part B best overall response was to be based on all responses taken from the start of Part B treatment until the start of any new anticancer therapy or disease progression in Part B. The duration of objective response was defined as the time of first objective response to the time of progression or death, whichever occurred first (or date of censoring for PFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response According to RECIST 1.1 in Part A</measure>
    <time_frame>tumour assessment was at screening (-28 days to screening) and every 6 weeks until the first follow-up visit in Part A, up to a total of 10 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective tumour response was defined as a best overall response of CR or PR as determined by RECIST 1.1 and as assessed by the Investigator. For patients enrolled in Part A, this was to be based on all responses taken from the start of treatment until the start of any new anticancer therapy or disease progression. Objective response was analysed descriptively. The duration of objective response was defined as the time of first objective response to the time of progression or death, whichever occurred first (or date of censoring for PFS).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1155</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Investigator`s choice of chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with investigator`s choice of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBW 2992 and Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigator´s choice of chemotherapy</intervention_name>
    <description>BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy</description>
    <arm_group_label>Investigator`s choice of chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBW 2992</intervention_name>
    <description>BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy</description>
    <arm_group_label>BIBW 2992 and Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Part A

          1. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with
             cytologically proven pleural effusion or pericardial effusion) or Stage IV who have
             failed treatment with erlotinib (Tarceva) or gefitinib (Iressa).

          2. Patients should have received and failed at least one line of cytotoxic chemotherapy
             including a platinum-based regimen in patients eligible for platinum-based therapy
             and pemetrexed in pemetrexed eligible patients (unless pemetrexed is not considered a
             regulatory or clinical standard of care e.g. no label indication, no availability or
             no coverage by 3rd party payer(s)) for advanced or metastatic disease and have
             progressive disease following at least 12 weeks of treatment with erlotinib or
             gefitinib

          3. Patients pretreated with taxane-based chemotherapy for advanced or metastatic disease
             must have experienced stable disease, partial or complete response as best response

          4. Eastern Cooperative Oncology Group performance Score 0 or 1.

          5. Patients with at least one tumor lesion that can accurately be measured by magnetic
             resonance imaging (MRI), or computed tomography (CT) in at least one dimension with
             longest diameter to be recorded as 10 mm but no less than double the slice thickness
             according to RESIST 1.1.

          6. Male and female patients no less than 18 years of age.

          7. Life expectancy of at least three (3) months.

          8. Written informed consent that is consistent with ICH-GCP guidelines. Part B 1)
             Clinical benefit (disease stabilization or antitumor response) of 12 weeks duration
             in Part A of the trial determined on the second tumour assessment.

        2.) Patients should have progressed in Part A according to RECIST 1.1 3.) New informed
        consent, including consent to biomarker sampling, must be signed before patients enter
        Part B of the trial

        Exclusion criteria:

          1. Previous treatment with BIBW 2992

          2. Chemo-, hormone- (other than megestrol acetate, steroids required for maintenance
             non-cancer therapy or as premedication before chemotherapy) or immunotherapy within
             the past 4 weeks; except for TKI pretreatment (2 weeks only)

          3. Active/symptomatic brain metastases including leptomeningeal disease. Patients with a
             history of treated brain metastasis must have a stable or normal brain MRT/CT scan at
             screening and be at least 4 weeks post-radiation or surgery for brain metastasis.
             Dexamethasone therapy will be allowed if administered as a stable dose for at least
             one month before randomization.

          4. Significant or recent acute gastrointestinal disorders with diarrhea as a major
             symptom e.g., Crohn's disease, mal-absorption, or CTCAE Grade &gt;2 diarrhea of any
             etiology at baseline

          5. Patients who have any other life-threatening illness or organ system dysfunction,
             which in the opinion of the Investigator, would either compromise patient safety or
             interfere with the evaluation of the safety of the test drug

          6. Other malignancies diagnosed within the past five (5) years (other than
             non-melanomatous skin cancer and in situ cervical cancer)

          7. Radiotherapy within the past 2 weeks prior to treatment with the trial drug

          8. History or presence of clinically relevant cardiovascular abnormalities such as
             uncontrolled hypertension, congestive heart failure New york Heart Association (NYHA)
             functional classification of 3, unstable angina, or poorly controlled arrhythmia.
             Myocardial infarction within 6 months prior to entering the trial.

          9. Cardiac left ventricular function with resting ejection fraction of less than 50%
             measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram
             .

         10. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or
             equivalent) at or greater than 400 mg/m2

         11. Absolute neutrophil count (ANC) at or less than 1500 / mm3

         12. Platelet count at or less than 100,000 / mm3

         13. Bilirubin at or greater than 1.5 mg / dL (&gt;26 mol / L, SI unit equivalent)

         14. Aspartate amino transferase (AST) or alanine amino transferase (ALT) at or greater
             than three times the upper limit of normal (if related to liver metastases at or
             greater than five times the upper limit of normal)

         15. Serum creatinine at or greater 1.5 times the upper normal limit or
             calculated/measured creatinine clearance at or less than 45 mL/min

         16. Women of child-bearing potential or men who are able to father a child unwilling to
             use a medically acceptable method of contraception during the trial

         17. Pregnancy or breast feeding

         18. Patients unable to comply with the protocol

         19. Patients with any serious active infection including known human immunodeficiency
             virus (HIV), active hepatitis B or active hepatitis C

         20. Known or suspected active drug or alcohol abuse

         21. Pre-existing or current Interstitial lung disease (ILD) 22.)

         22. Peripheral polyneuropathy of &gt; Grade 2

         23. Requirement for treatment with any of the pohibited concomitant medication listed in
             section 4.2.2.1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.42.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.61005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.61002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.61001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.61003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Duffel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middelheim</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.55004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.86013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen Cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Caen cedex 5</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lyon Cedex 08</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris cedex 20</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint-Herblain cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Törökbálint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashik, Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.97203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.97204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.97201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aviano (PN)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monza (mi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hwasun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.52003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Distrito Federal</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.51002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.51001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Victoria</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.48006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.48002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.48004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Otwock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.48001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obninsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mataró</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88610 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovks</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sutton, Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1200.42.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Truro, Cornwall</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 9, 2016</lastchanged_date>
  <firstreceived_date>March 10, 2010</firstreceived_date>
  <firstreceived_results_date>October 1, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Afatinib Monotherapy</title>
          <description>Test product for Part A: Afatinib film-coated tablet dose: 50 mg/day, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral</description>
        </group>
        <group group_id="P2">
          <title>Afatinib Plus Paclitaxel</title>
          <description>Test product for Part B: Afatinib film-coated tablet dose: 40 mg/day, with dose reductions to 30 mg/day and 20 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Concomitant therapy for Part B:Paclitaxel dose: 80 mg/m2 once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol-defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous</description>
        </group>
        <group group_id="P3">
          <title>Investigators Choice of Chemotherapy</title>
          <description>Reference therapy for Part B:Investigators choice of chemotherapy dose: Depending on schedule (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous or oral, depending on schedule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1154"/>
                <participants group_id="P2" count="0">Only Afatinib monotherapy administered in Part A</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="832">On-going, progressive disease, clinical progression and discontinued Part A -randomized to Part B</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to continue trial medication</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not given</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Afatinib monotherapy not administered in Part B</participants>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="86">Completed trial as per protocol, had progressive disease, clinical signs or symptoms of progression</participants>
                <participants group_id="P3" count="42">Completed trial as per protocol, had progressive disease, clinical signs or symptoms of progression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal to continue trial medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not given</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set, i.e. all patients who were documented to have taken at least 1 dose of afatinib 50 mg in Part A of the trial and all patients who received at least 1 dose of trial medication in Part B.</population>
      <group_list>
        <group group_id="B1">
          <title>Part A: Afatinib Monotherapy</title>
          <description>Test product for Part A: Afatinib film-coated tablet dose: 50 mg/day, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1154"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60.1" spread="10.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="654"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="500"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) Time as Determined by RECIST 1.1 for Part B.</title>
        <description>PFS from the day of randomisation to the day of progression according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 for patients randomised to combination therapy with afatinib plus paclitaxel or to investigators choice of chemotherapy.</description>
        <time_frame>Every 8 weeks until the final follow-up visit in Part B, up to a total of 10 years.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomised set - all randomised patients irrespective of whether treated or not</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Afatinib Plus Paclitaxel</title>
            <description>Test product for Part B: Afatinib film-coated tablet dose: 40 mg/day, with dose reductions to 30 mg/day and 20 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Concomitant therapy for Part B:Paclitaxel dose: 80 mg/m2 once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol-defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Part B:Investigators Choice of Chemotherapy</title>
            <description>Reference therapy for Part B:Investigators choice of chemotherapy dose: Depending on schedule (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous or oral, depending on schedule</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival (PFS) Time as Determined by RECIST 1.1 for Part B.</title>
            <description>PFS from the day of randomisation to the day of progression according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 for patients randomised to combination therapy with afatinib plus paclitaxel or to investigators choice of chemotherapy.</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="5.59" lower_limit="5.06" upper_limit="6.31"/>
                  <measurement group_id="O2" value="2.79" lower_limit="1.71" upper_limit="3.94"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis of the primary analysis was that PFS is longer for patients treated with afatinib plus paclitaxel than for those who received ICC. HA: (S)AFATINIB+PACLITAXEL (t)&gt;(S)ICC (t), for t&gt;0 The null hypothesis: H0: (S)AFATINIB+PACLITAXEL (t)≤(S)ICC (t), for t&gt;0 where S(t) was the probability that a patient passes time t without progressing or dying. The null hypothesis was tested at the two-sided 0.05 level.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0031</p_value>
            <p_value_desc>P−value is calculated from two−sided stratified log−rank test.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Hazard ratio from Cox proportional hazard model with treatment as the only factor,stratified by gender and maximum duration of erlotinib or gefitinib.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) as Determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A</title>
        <description>Progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A. PFS from the day of randomisation to the day of progression according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 for patients treated with Afatinib monotherapy.</description>
        <time_frame>tumour assessment was at screening (-28 days to screening) and every 6 weeks until the first follow-up visit in Part A, up to a total of 10 years.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set - all patients who were documented to have taken at least 1 dose of afatinib 50 mg in Part A of the trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Monotherapy</title>
            <description>Test product for Part A: Afatinib film-coated tablet dose: 50 mg/day, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival (PFS) as Determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A</title>
            <description>Progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for Part A. PFS from the day of randomisation to the day of progression according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 for patients treated with Afatinib monotherapy.</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.15" lower_limit="2.83" upper_limit="3.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) as Determined by the Time From Randomization to Death in Part B</title>
        <description>Overall survival was calculated as the time from the date of randomisation to the date of death. Patients for whom there was no evidence of death at the time of the analysis were to be censored on the date that they were last known to have been alive.</description>
        <time_frame>from the date of randomisation to the date of death, up to a total of 10 years.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomised set - all randomised patients irrespective of whether treated or not</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Afatinib Plus Paclitaxel</title>
            <description>Test product for Part B: Afatinib film-coated tablet dose: 40 mg/day, with dose reductions to 30 mg/day and 20 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Concomitant therapy for Part B:Paclitaxel dose: 80 mg/m2 once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol-defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Part B:Investigators Choice of Chemotherapy</title>
            <description>Reference therapy for Part B:Investigators choice of chemotherapy dose: Depending on schedule (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous or oral, depending on schedule</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Survival (OS) as Determined by the Time From Randomization to Death in Part B</title>
            <description>Overall survival was calculated as the time from the date of randomisation to the date of death. Patients for whom there was no evidence of death at the time of the analysis were to be censored on the date that they were last known to have been alive.</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.16" lower_limit="10.18" upper_limit="14.88"/>
                  <measurement group_id="O2" value="12.22" lower_limit="9.33" upper_limit="16.59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A stratified log-rank test was used to test the effect of therapy with afatinib plus paclitaxel on OS compared with ICC. The test was stratified by the duration of clinical benefit with erlotinib or gefitinib and sex. A Cox proportional hazards model, stratified by duration of clinical benefit to erlotinib or gefitinib and sex was used to estimate the Hazard Ratio and 95% CI between the 2 treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.9936</p_value>
            <p_value_desc>P−value is calculated from two−sided stratified log−rank test.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate According to RECIST 1.1 in Part B</title>
        <description>Objective tumour response was defined as a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 and as assessed by the Investigator. For patients enrolled in Part B, a Part B best overall response was to be based on all responses taken from the start of Part B treatment until the start of any new anticancer therapy or disease progression in Part B. The duration of objective response was defined as the time of first objective response to the time of progression or death, whichever occurred first (or date of censoring for PFS).</description>
        <time_frame>tumour assessment was every 8 weeks until the final follow-up visit in Part B, up to a total of 10 years.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Randomised set - all randomised patients irrespective of whether treated or not</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Afatinib Plus Paclitaxel</title>
            <description>Test product for Part B: Afatinib film-coated tablet dose: 40 mg/day, with dose reductions to 30 mg/day and 20 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Concomitant therapy for Part B:Paclitaxel dose: 80 mg/m2 once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol-defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous</description>
          </group>
          <group group_id="O2">
            <title>Part B:Investigators Choice of Chemotherapy</title>
            <description>Reference therapy for Part B:Investigators choice of chemotherapy dose: Depending on schedule (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous or oral, depending on schedule</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Objective Response Rate According to RECIST 1.1 in Part B</title>
            <description>Objective tumour response was defined as a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 and as assessed by the Investigator. For patients enrolled in Part B, a Part B best overall response was to be based on all responses taken from the start of Part B treatment until the start of any new anticancer therapy or disease progression in Part B. The duration of objective response was defined as the time of first objective response to the time of progression or death, whichever occurred first (or date of censoring for PFS).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A logistic regression model stratified by duration of clinical benefit to erlotinib or gefitinib and sex was used to determine objective response rates with exact 95% Clopper-Pearson CIs for Part B.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0049</p_value>
            <p_value_desc>Odds ratio, 95% CI and p−value (two−sided) from logistic regression stratified for maximum treatment duration of prior erlotinib or gefitinib (&gt;=6 months vs &lt;6 months) and gender.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.093</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.408</ci_lower_limit>
            <ci_upper_limit>6.794</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response According to RECIST 1.1 in Part A</title>
        <description>Objective tumour response was defined as a best overall response of CR or PR as determined by RECIST 1.1 and as assessed by the Investigator. For patients enrolled in Part A, this was to be based on all responses taken from the start of treatment until the start of any new anticancer therapy or disease progression. Objective response was analysed descriptively. The duration of objective response was defined as the time of first objective response to the time of progression or death, whichever occurred first (or date of censoring for PFS).</description>
        <time_frame>tumour assessment was at screening (-28 days to screening) and every 6 weeks until the first follow-up visit in Part A, up to a total of 10 years.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Treated set - all patients who were documented to have taken at least 1 dose of afatinib 50 mg in Part A.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib Monotherapy</title>
            <description>Test product for Part A: Afatinib film-coated tablet dose: 50 mg/day, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Objective Response According to RECIST 1.1 in Part A</title>
            <description>Objective tumour response was defined as a best overall response of CR or PR as determined by RECIST 1.1 and as assessed by the Investigator. For patients enrolled in Part A, this was to be based on all responses taken from the start of treatment until the start of any new anticancer therapy or disease progression. Objective response was analysed descriptively. The duration of objective response was defined as the time of first objective response to the time of progression or death, whichever occurred first (or date of censoring for PFS).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the signing of the informed consent to the final follow-up visit.</time_frame>
      <desc>Part A-events that started within the period defined by the first administration of afatinib until randomization into Part B or 28 days after the last administration of afatinib, whichever occurred first. Part B -events that started within the period from randomization through 28 days after the last administration of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part A: Afatinib Monotherapy</title>
          <description>Test product for Part A: Afatinib film-coated tablet dose: 50 mg/day, with dose reductions to 40 mg/day and 30 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Median duration of exposure was 86.0 days.</description>
        </group>
        <group group_id="E2">
          <title>Part B: Afatinib Plus Paclitaxel</title>
          <description>Test product for Part B: Afatinib film-coated tablet dose: 40 mg/day, with dose reductions to 30 mg/day and 20 mg/day (following the protocol-defined dose reduction scheme) mode of admin.: Oral
Concomitant therapy for Part B:Paclitaxel dose: 80 mg/m2 once weekly (7 weeks on/1 week off; 2 dose reductions were allowed following the protocol-defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous
Median duration of exposure was 132.5 days.</description>
        </group>
        <group group_id="E3">
          <title>Part B:Investigators Choice of Chemotherapy</title>
          <description>Reference therapy for Part B:Investigators choice of chemotherapy dose: Depending on schedule (2 dose reductions were allowed following the protocol defined dose reduction scheme and the current local summary of product characteristics) mode of admin.: Intravenous or oral, depending on schedule.
Median duration of exposure was 50.5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="468" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting projectile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gravitational oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Performance status decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy lymph gland abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Gene mutation identification test</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pericarditis malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tumour compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thoracic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Partial lung resection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neurogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1111" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="927" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="247" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="302" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="341" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="299" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="628" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="1154"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
